This Amendment No. 1 to Statement of Beneficial Ownership on Schedule 13D (this “Amendment No. 1”) amends the Statement of Beneficial Ownership on Schedule 13D filed by Jeff Toghraie on September 9, 2022 (as amended, the “Schedule 13D” or this “Statement”). Capitalized terms used but not defined in this Amendment No. 1 shall have the meanings set forth in the Schedule 13D. Except as amended and supplemented by this Amendment No. 1, the Schedule 13D remains unchanged.
Item 1. Security and Issuer.
This Statement relates to the common stock, $0.0001 par value per share (the “Common Stock”), of Reviv3 Procare Company, a Delaware corporation (the “Company”). The Company reports that its principal executive offices are located at 901 Fremont Avenue, Unit 158 and Unit 168, Alhambra, California 91803.
Item 4. Purpose of Transaction.
On April 10, 2023, Axil & Associated Brands Corp., a Delaware corporation (“Axil”), engaged in a distribution, pursuant to which Intrepid, a stockholder of Axil, received 15,000,000 shares of Common Stock, for no consideration.
Mr. Toghraie acquired the shares of Common Stock reported in this Statement for investment purposes. Mr. Toghraie may in the future acquire additional shares of Common Stock or dispose of some or all of the shares of Common Stock beneficially owned by him in open-market transactions or privately negotiated transactions, on such terms and at such times as he may deem advisable.
Mr. Toghraie does not have any present plan or proposal that would result in any of the actions described in paragraphs (a) through (j) of Item 4 of Schedule 13D, except as set forth herein or as may be proposed by Mr. Toghraie in his capacity as an officer or director of the Company or by the Board of Directors with his participation. Mr. Toghraie reserves the right in the future to formulate any such plans or proposals, and to take any actions with respect to his investments in the Company, including any or all of the actions described in paragraphs (a) through (j) of Item 4 of Schedule 13D.
Item 5. Interest in Securities of the Issuer.
| (a) | Mr. Toghraie beneficially owns in the aggregate 24,827,750 shares of Common Stock, which represents approximately 20.9% of the Company’s outstanding shares of Common Stock and includes the following: |
| · | 23,084,000 shares of Common Stock directly held by Intrepid. Mr. Toghraie, as the managing director and beneficiary of Intrepid, may be deemed to beneficially own the shares of Common Stock directly held by Intrepid. |
| · | Options to purchase an aggregate of 1,743,750 shares of Common Stock that are exercisable within 60 days of the filing of this Statement and were received as part of his executive officer compensation. Mr. Toghraie holds options to purchase 3,100,000 shares of Common Stock at an exercise price of $0.09 per share, of which 1,743,750 are exercisable within 60 days of the filing of this Statement. These options were granted May 10, 2022, expire April 20, 2032, and vest as follows: 25% of the original grant amount vested September 1, 2022 and the remainder vests in 24 equal monthly installments on the first day of each month, beginning October 1, 2022. |
Each percentage ownership of Common Stock set forth in this Statement is based on 117,076,949 shares of Common Stock reported by the Company as outstanding as of April 12, 2023 in its Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on April 12, 2023.
| (c) | On April 10, 2023, Axil engaged in a distribution, pursuant to which Intrepid, a stockholder of Axil, received 15,000,000 shares of Common Stock, for no consideration. |